



## 2012 Registration Document Filed

Charenton-le-Pont, France (April 3, 2013 - 6:00 p.m.) – The 2012 Essilor Registration Document was filed in French version with the *Autorité des Marchés Financiers* (AMF) on April 2, 2013 under the number D.13-0252. The Registration Document includes:

- a) The Annual Financial Report, with:
  - The parent company financial statements;
  - The consolidated financial statements;
  - A management report containing information in compliance with articles L.225-100, L.225-100-3, L.225-11 (§ 2) and L.225-100-2 of the French Commercial Code;
  - A statement by the persons responsible for the Registration Document;
  - The report of the Auditors on the parent company and consolidated financial statements;
  - Information concerning Auditors' fees.
- b) The Chairman's report on corporate governance and internal control.
- c) The description of the share buyback program.

From now on, the French version is available to the public free of charge, as provided for in applicable legislation, and may be viewed on Essilor's corporate website [www.essilor.com](http://www.essilor.com). The English version will be available in a few days.

### **About Essilor**

*The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux<sup>®</sup>, Crizal<sup>®</sup>, Definity<sup>®</sup>, Xperio<sup>®</sup>, Optifog<sup>™</sup> and Foster Grant<sup>®</sup>. It also develops and markets equipment, instruments and services for eyecare professionals.*

*Essilor reported consolidated revenue of approximately €5 billion in 2012 and employs around 50,700 people in some 100 countries. It operates 22 plants, more than 400 prescription laboratories and edging facilities, as well as several research and development centers around the world.*

*For more information, please visit [www.essilor.com](http://www.essilor.com).*

*The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.*

*Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.*